Navigation Links
Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)
Date:11/26/2007

LONDON, November 26 /PRNewswire/ -- Daval International Limited, a UK private company, announces MHRA and IRB (Ethics Committee) approval of a London based Phase IIB trial of AIMSPRO(R), its hyperimmune caprine serum derivative.

This double-blind placebo-controlled cross-over study will seek to detect a beneficial effect on bladder function in patients with Secondary Progressive Multiple Sclerosis, following open-label observations over several years in a number of informed consent, "compassionate basis" patients.

AIMSPRO has an "export only" listing on the Australian Registry of Therapeutic Goods and a TGA Orphan Status Designation for the treatment of Krabbe's disease. An IND application is being lodged for a further MS trial in the United States.

AIMSPRO is a frozen medication, given as a 1ml sub-cutaneous injection every 4 days. It is believed to have a pronounced and sustained anti-inflammatory action with an associated, novel effect of lowering sodium channel triggering voltages in nerve fibres. MHRA applications for two further clinical trials are to be lodged within the next 3months.

Daval International Ltd. has recently been accepted as a member of the Association of the British Pharmaceutical Industry. "APBI"

Daval International Limited

Daval International Limited is a privately owned British pharmaceutical company, which, since 2001, has been developing an immunologically active human and veterinary medication derived from goat serum. Some 20.000 doses of Aimspro have been administered, mainly to human subjects with multiple sclerosis, with an excellent safety and tolerance profile.


'/>"/>
SOURCE Daval International Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
3. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
4. Arrow International Files and Mails Definitive Proxy Materials
5. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
6. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
7. Viragen International to Reverse Split Its Common Stock
8. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
9. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
10. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
11. Biosafety and Biosecurity International Conference 2007 to be held in Abu Dhabi from November 12 to 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... San Diego, CA (PRWEB) , ... June 27, 2016 , ... ... mClinical solutions for clinical trials, announced today the Clinical Reach Virtual Patient ... and their care circle with the physician and clinical trial team. , Using the ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):